Companies Dominating the Thiamine Mononitrate (Vitamin B1) Landscape
- Brother Enterprises Holding Co., Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- BASF SE
- Jiangxi Tianxin Pharmaceutical Co., Ltd.
- Koninklijke DSM N.V.
- Supreem Pharmaceuticals Mysore Pvt. Ltd.
- Saltvae Pharmaceuticals Private Limited
- Charles Bowman and Company
- Huazhong Pharmaceutical Co., Ltd.
- Xinfa Pharmaceutical Co. Ltd.
- CMG BIOTECH PRIVATE LIMITED
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of thiamine mononitrate is assessed at USD 807.32 million.
The thiamine mononitrate market size was over USD 747.56 million in 2024 and is anticipated to cross USD 1.39 billion by 2037, growing at more than 4.9% CAGR during the forecast period i.e., between 2025-2037. Increasing demand The surge in the underweight issue, the worldwide rising geriatric population, and an upsurge in the demand for health supplements will boost the market growth.
Asia Pacific industry is likely to hold largest revenue share of 44% by 2037, attributed to increasingly high demand for dietary supplements and vitamins in the region.
The major players in the market are Brother Enterprises Holding Co., Ltd., BASF SE, Jiangxi Tianxin Pharmaceutical Co., Ltd., Koninklijke DSM N.V., Supreem Pharmaceuticals Mysore Pvt. Ltd., Saltvae Pharmaceuticals Private Limited, Charles Bowman and Company, Huazhong Pharmaceutical Co., Ltd., Xinfa Pharmaceutical Co. Ltd., CMG BIOTECH PRIVATE LIMITED
